HAVCR1 and diabetic kidney disease: In any case, further clinical studies are needed to clarify whether a therapeutic dose of apixaban could attenuate renal injury evaluated by urinary excretion levels of KIM-1 and protein in patients with diabetic nephropathy via the suppression of the AGE-RAGE-oxidative stress axis.